Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations

The drug olaparib (Lynparza®) is the first treatment approved by the Food and Drug Administration for patients with metastatic breast cancer who have inherited mutations in the BRCA1 or BRCA2 genes.

Cancer Currents: An NCI Cancer Research Blog